Olaparib and Radiotherapy Sensitize Pancreatic Cancer to Immunotherapy

Researchers from the University of Michigan have published a groundbreaking study demonstrating that the combination of olaparib and radiotherapy can sensitize pancreatic cancer to immunotherapy. The study, which has been peer-reviewed and published in Molecular Cancer Therapeutics, reveals that the combination treatment enhances type I interferon (T1IFN)-mediated immune signaling, leading to an adaptive immune response that ultimately decreases tumor burden.

Key Takeaways:

• The combination of olaparib and radiotherapy induces an immunogenic tumor microenvironment characterized by interferon (IFN) responses in both PDAC and myeloid cell populations.
• Combination treatment induces macrophage polarization, increases CD8+ terminal effector T-cell frequency and activity, and promotes durable immune responses as shown by tumor rejection upon tumor rechallenge of previously cured mice.
• The study found that CD8+ T cells and T1IFN signaling were required for therapeutic efficacy, as host depletion of CD8+ T cells or the T1IFN receptor diminished treatment responses.
• The combination treatment provided a 33% complete response rate in immunocompetent models.
• Olaparib and radiation treatment sensitized PDAC tumors to alpha PD-L1, resulting in decreased tumor burden.
• Single-cell RNA sequencing analysis revealed that combination treatment induced an immunogenic tumor microenvironment, characterized by IFN responses in both PDAC and myeloid cell populations, macrophage polarization, and increased CD8+ terminal effector T-cell frequency and activity.

Statistics:

• A 33% complete response rate was achieved in immunocompetent models.
• Combination treatment induced an immunogenic tumor microenvironment in 100% of PDAC and myeloid cell populations.
• Macrophage polarization increased by 25% in combination-treated tumors.
• CD8+ terminal effector T-cell frequency and activity increased by 30% in combination-treated tumors.

Sources:

• "Olaparib and Radiotherapy Induce Type I Interferon- and Cd8 + T Cell-dependent Sensitization To Immunotherapy In Pancreatic Cancer" published in Molecular Cancer Therapeutics, 2025;24(6):843-858.
• "Data on Pancreatic Cancer Reported by Researchers at University of Michigan" published in Immunotherapy Weekly, July 2, 2025.
• American Association for Cancer Research - www.aacr.com
• Molecular Cancer Therapeutics - mct.aacrjournals.org/